Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Dr Pierotti discusses how putting together a vast group of partners creates a network that will allow for a patient to receive the best possible treatment. The combined information will allow new targets and new drugs and the expansion of almost two dozen projects within the Lombardy region.
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
Understanding the use of PARPi combinations to treat patients with mCRPC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Addressing the rise of multiple myeloma in Rwanda
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Uncommon genetic aberrations NTRK, RET, NRG
ASCO 2024: Lung cancer highlights